Clinical Trial Update: Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the safety and immunogenicity of three recombinant live-attenuated RSV vaccines in RSV-seronegative children aged 6 to 24 mo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV 276
• RSV 6120/∆NS2/1030s
• RSV ΔNS2/Δ1313/I1314L

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Respiratory Syncytial Virus (RSV) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-02-21